If these states do move forward with the legalization of adult use recreational cannabis, the fight for the end of nationwide cannabis prohibition could be reaching its finale.
Gold rises from daily lows
Gold rose from daily lows following the data release, with December Comex gold futures last trading at $1,867.30, down 0.16% on the day.
Gold, silver and platinum find new levels
The bullish action shows us this consolidation at higher levels than before.
Psychedelics-Assisted Therapy: Effective, Economical AND Imperative
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
Gold prices rise as inflation risks persist
Higher interest rates increase the opportunity cost of holding non-interest bearing gold.
Silver demand to surpass 1 billion ounces this year, hitting a 6-year high
The global silver market will see demand reach 1.29 billion ounces this year, the first time it has breached 1 billion since 2015.
Combination of gold, bitcoin and bonds to beat inflation
The investment environment will be changing in 2022, and a combination of gold, bitcoin and bonds could be the winning one, according to Bloomberg Intelligence.
Hedge funds scrambling for gold
The growing inflation threat has shifted sentiment in the gold market, with hedge funds significantly increasing their bullish precious metals bets to protect their wealth.
Lawmakers File Bill to Federally Legalize Cannabis
The States Reform Act seeks to end the federal prohibition of cannabis.
Novamind Signs LOI to Acquire Two Mental Health Clinics in Arizona
Novamind announces an LOI to add two Arizona mental health clinics to its treatment network.
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
